|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: APITD1 |
Gene summary for APITD1 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | APITD1 | Gene ID | 378708 |
| Gene name | centromere protein S | |
| Gene Alias | APITD1 | |
| Cytomap | 1p36.22 | |
| Gene Type | protein-coding | GO ID | GO:0000003 | UniProtAcc | Q8N2Z9 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 378708 | APITD1 | C04 | Human | Oral cavity | OSCC | 5.36e-10 | 5.38e-01 | 0.2633 |
| 378708 | APITD1 | C21 | Human | Oral cavity | OSCC | 2.49e-29 | 8.58e-01 | 0.2678 |
| 378708 | APITD1 | C30 | Human | Oral cavity | OSCC | 1.39e-28 | 1.29e+00 | 0.3055 |
| 378708 | APITD1 | C43 | Human | Oral cavity | OSCC | 4.74e-25 | 4.30e-01 | 0.1704 |
| 378708 | APITD1 | C46 | Human | Oral cavity | OSCC | 1.26e-29 | 6.56e-01 | 0.1673 |
| 378708 | APITD1 | C51 | Human | Oral cavity | OSCC | 2.94e-06 | 4.02e-01 | 0.2674 |
| 378708 | APITD1 | C57 | Human | Oral cavity | OSCC | 6.67e-05 | 2.85e-01 | 0.1679 |
| 378708 | APITD1 | C06 | Human | Oral cavity | OSCC | 2.00e-02 | 7.22e-01 | 0.2699 |
| 378708 | APITD1 | C08 | Human | Oral cavity | OSCC | 1.58e-09 | 2.93e-01 | 0.1919 |
| 378708 | APITD1 | LN22 | Human | Oral cavity | OSCC | 2.34e-05 | 6.35e-01 | 0.1733 |
| 378708 | APITD1 | LN46 | Human | Oral cavity | OSCC | 5.19e-16 | 6.13e-01 | 0.1666 |
| 378708 | APITD1 | LP15 | Human | Oral cavity | LP | 2.70e-10 | 9.37e-01 | 0.2174 |
| 378708 | APITD1 | LP17 | Human | Oral cavity | LP | 7.63e-09 | 7.37e-01 | 0.2349 |
| 378708 | APITD1 | SYSMH1 | Human | Oral cavity | OSCC | 7.86e-05 | 1.44e-01 | 0.1127 |
| 378708 | APITD1 | SYSMH2 | Human | Oral cavity | OSCC | 5.66e-05 | 1.75e-01 | 0.2326 |
| 378708 | APITD1 | SYSMH3 | Human | Oral cavity | OSCC | 1.57e-04 | 2.17e-01 | 0.2442 |
| 378708 | APITD1 | P1_cSCC | Human | Skin | cSCC | 2.83e-15 | 4.42e-01 | 0.0292 |
| 378708 | APITD1 | P2_cSCC | Human | Skin | cSCC | 9.47e-12 | 2.47e-01 | -0.024 |
| 378708 | APITD1 | P4_cSCC | Human | Skin | cSCC | 1.60e-12 | 2.54e-01 | -0.00290000000000005 |
| 378708 | APITD1 | P10_cSCC | Human | Skin | cSCC | 1.80e-06 | 1.86e-01 | 0.1017 |
| Page: 1 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| Page: 1 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |